Tunitas Therapeutics is developing novel therapeutics that target inhibitory pathways on allergic cells, effectively inhibiting key mediators of allergic hypersensitivity and IgE production. This breakthrough treatment offers long-lasting benefits, transforming the lives of patients with serious allergic diseases such as asthma and severe food allergies. With Tunitas' fusion proteins, patients can receive treatment in their allergist's office, altering the natural course of their disease and providing a therapeutic option for any IgE-mediated condition.